Navigation Links
Noninvasive combination technique may reduce number of breast biopsies

OAK BROOK, Ill. By combining two relatively inexpensive technologies based on sound and light waves, researchers hope to lower the rate at which women undergo breast biopsies for suspicious lesions. Results of the study on ultrasound-guided optical tomography are published in the online edition and the August print issue of Radiology.

"The goal of our study was to investigate the potential of diffuse optical tomography in the near infrared spectrum with ultrasound localization as a means of differentiating early-stage cancers from benign lesions of the breast," said lead researcher Quing Zhu, Ph.D., professor of bioengineering at the University of Connecticut.

When mammography and ultrasound cannot determine whether a suspicious breast lesion is malignant or benign, physicians typically recommend a needle biopsy to extract samples of the suspicious tissue for laboratory testing. In current clinical practice, 70 to 80 percent of biopsies performed reveal benign lesions, leading to unnecessary cost and anxiety for women.

Diffuse optical tomography is an emerging noninvasive imaging technique that measures light absorption within tissue to quantify blood content (hemoglobin level) and blood oxygen levels. Because cancerous lesions have many more blood vessels than normal tissue, hemoglobin levels can help distinguish malignant from benign lesions.

In Dr. Zhu's study, 178 consecutive women underwent ultrasound-guided diffuse optical tomography (DOT) on a previously identified solid lesion, followed by a biopsy. The study, which included women between the ages of 21 and 89 years, was conducted between 2004 and 2008 at the University of Connecticut Health Center and Hartford Hospital, both in Hartford, Conn.

Performing ultrasound-guided DOT involves the use of a handheld probe consisting of a commercial ultrasound transducer located in the middle and an optical source and detector fibers around the periphery. Once ultrasound locates the lesion, DOT is performed by shining infrared light into the area and measuring light absorption at two optical wavelengths.

"Infrared light penetrates deep into tissue, up to four centimeters," Dr. Zhu said.

Researchers computed total hemoglobin levels from the light absorption measured at two wavelengths and correlated the measurements with biopsy results. Laboratory examination of tissue samples revealed two in situ carcinomas, 35 carcinomas that measured less than two centimeters, 24 carcinomas greater than two centimeters and 114 benign lesions.

"Both maximum and average total hemoglobin levels were significantly higher in the malignant groups than in the benign group," Dr. Zhu said.

The sensitivity and specificity of the technique (92 percent and 93 percent, respectively) were greatest when evaluating cancers less than two centimeters in size.

"Based on our results, we believe that ultrasound-guided diffuse optical tomography holds promise as an adjunct to diagnostic mammography and ultrasound for distinguishing early-stage invasive breast cancers from benign lesions," Dr. Zhu said. "We expect this technology will be used to help radiologists evaluate small to intermediate size lesions that are harder to diagnose with conventional imaging technologies."

Ultrasound and near infrared procedures cost significantly less than magnetic resonance imaging (MRI), another technique used to evaluate suspicious breast lesions that cannot be diagnosed using mammography.

The next step in Dr. Zhu's research, which is supported by grants totaling $1.4 million from the National Institutes of Health with additional $600,000 support from the Donaghue Medical Research Foundation, is to design multi-institution clinical trials for ultrasound-guided DOT.


Contact: Linda Brooks
Radiological Society of North America

Related medicine news :

1. New research shows innovative respiratory stress test can quickly detect significant coronary artery disease in a noninvasive setting
2. New combination effective against pancreatic cancer
3. Combination treatment regimen not effective against advanced melanoma
4. Combination therapy targets stubborn leukemia stem cells
5. Hair Loss Doctor Overcomes Odds To Produce First Ever Combination Topical Hair Growth Formula
6. Combination antibiotics effective against chlamydia-induced arthritis
7. Leeza Gibbons and ZERONA Equals a Winning Combination
8. Researchers find new chemotherapy combination shows promise in endometrial cancer
9. Combination Treatment May Help Depressed Alcoholics
10. Combination therapy more effective for enlarged prostate
11. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
Post Your Comments:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: